Bronchodilators: Beta-2 Agonists, Muscarinic Antagonists and Clinical Safety

Medical education article updated 10 November 2026. Prescribing should follow current local clinical guidelines and product information.

Overview

Bronchodilators relax bronchial smooth muscle and improve airflow in asthma and COPD. They relieve obstruction but do not universally control airway inflammation: this distinction is especially important in asthma, where inhaled corticosteroid (ICS)-containing therapy is needed to prevent serious attacks [1–3].

Mechanisms and classification

  • Short-acting β2 agonists (SABA): albuterol/salbutamol, levalbuterol and terbutaline stimulate β2-adrenoceptors, activate Gs/adenylyl cyclase and raise cAMP, relaxing airway smooth muscle.
  • Long-acting β2 agonists (LABA): formoterol, salmeterol, indacaterol, olodaterol and vilanterol. Formoterol acts rapidly, whereas salmeterol is relatively slower; long duration does not imply rapid onset.
  • Short-acting muscarinic antagonist (SAMA): ipratropium competitively blocks airway M3 receptors.
  • Long-acting muscarinic antagonists (LAMA): tiotropium, glycopyrronium and umeclidinium inhibit cholinergic bronchoconstriction over prolonged periods.
  • Methylxanthines: theophylline inhibits phosphodiesterases and antagonizes adenosine receptors but has a narrow therapeutic window and limited routine role [1].

Uses in asthma and COPD

For asthma, β2 agonists provide bronchodilation, but SABA-only treatment is not recommended under GINA 2026. Low-dose ICS-formoterol is the preferred reliever for adults/adolescents when available and appropriate, with age-specific alternatives. LABA must not be used without ICS in asthma. In COPD, long-acting LABA and/or LAMA therapy is central; dual LABA/LAMA often improves symptoms, while triple therapy depends on exacerbation history and eosinophil-informed assessment [2,3].

Pharmacokinetics and formulations

Inhaled routes deliver high local exposure with lower systemic exposure than oral routes, but deposition depends on device, technique and inspiratory flow. Long action of tiotropium relates mainly to slow dissociation from M3 receptors, not simply a long plasma half-life. LABAs differ in intrinsic efficacy, onset, lipophilicity and residence time; product-specific instructions matter [1].

Adverse effects and interactions

β2 agonists can cause tremor, tachycardia, palpitations and dose-related hypokalemia; high-dose treatment warrants electrolyte and cardiac monitoring. Muscarinic antagonists can cause dry mouth and may worsen urinary retention; avoid spraying into eyes, particularly with narrow-angle glaucoma. Theophylline can cause vomiting, arrhythmias and seizures, and its concentrations are affected by smoking, liver disease, infection and interacting medicines such as certain macrolides and quinolones [1].

Acute care and exclusions

In severe asthma, repeated inhaled SABA, systemic corticosteroids, oxygen and add-on ipratropium may be required; IV magnesium sulfate is an adjunct in selected nonresponders, not a routine maintenance bronchodilator. Propofol is an anesthetic with potential bronchodilatory properties, not an outpatient bronchodilator class [2].

Key takeaways

Use the correct inhaler and technique, distinguish rescue from controller therapy and assess response, safety and inflammatory disease control. Not every LABA-containing inhaler is an appropriate asthma reliever [2,3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Global Initiative for Asthma. 2026 summary guide for asthma management and prevention. Available from: https://ginasthma.org/2026-gina-summary-guide/
  3. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2026 report. Available from: https://goldcopd.org/2026-gold-report-and-pocket-guide/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *